Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are exploring the integration of early dementia detection into Ainnova's Vision AI platform. The companies are considering either licensing or acquiring a patented technology that uses AI algorithms and hardware for dementia detection through a 5-minute blood test.

The Vision AI platform currently employs 4 integrated algorithms to assess risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images, blood pressure, and lab test data. The system utilizes an automated, low-cost retinal imaging device for comprehensive preventive risk screening.

Positive

• Potential expansion into dementia detection market through patented technology
• Existing comprehensive platform already screens for multiple major diseases
• Technology offers rapid results through 5-minute blood test
• Low-cost, automated screening system enhances accessibility

Negative

• Technology acquisition/licensing still in exploratory phase with no definitive agreement
• Integration timeline and costs not disclosed
• No mention of regulatory approvals or clinical validation status

LAS VEGAS, May 27, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are exploring options to integrate the early detection of dementia into Ainnova's proprietary, AI-powered platform technology, Vision AI.  The addition would reinforce the Company's mission of expanding AI-powered early detection and preventative health solutions across the globe. 

Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether.  The patented technology combines AI algorithms and hardware based on a 5-minute blood test.  Adding the early detection of dementia would expand the offerings in the Company's technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova.  

The success of the Company's preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening.  Presently, from just two retinal images, blood pressure and some lab test information, the Company's system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD).

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the potential expansion of its technology portfolio, "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.  Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection."

About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare.  With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com 

You can also follow us on social media at:

https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai 
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements."  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies, Inc. info@avanttechnologies.com

 

Video - https://mma.prnewswire.com/media/2696590/Avant_Technologies.mp4
Logo - https://mma.prnewswire.com/media/2370694/5338617/Avant_Technologies.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-ainnova-explore-integrating-early-detection-of-dementia-into-ai-powered-preventative-screening-platform-302465664.html

SOURCE Avant Technologies Inc.

FAQ

What diseases can Avant Technologies' (AVAI) Vision AI platform currently detect?

The Vision AI platform currently screens for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images, blood pressure, and lab test data.

How does AVAI's new dementia detection technology work?

The patented technology combines AI algorithms with hardware to detect dementia early through a 5-minute blood test, though it's still in the exploration phase for integration.

What is the partnership between Avant Technologies (AVAI) and Ainnova Tech?

Avant Technologies and Ainnova Tech are joint venture partners working together on AI-powered early disease detection technology through their Vision AI platform.

How does Avant Technologies' (AVAI) Vision AI screening system work?

The system uses an automated, low-cost retinal imaging device that captures two retinal images, combined with blood pressure and lab test information, to assess disease risks through 4 integrated algorithms.